448 THERAPEUTICS
448 Therapeutics focuses on the research and experimental development of biotechnology. It is a biotechnology company that engages in creating novel immuno-oncology drugs.
448 THERAPEUTICS
Industry:
Biotechnology Life Science Product Research
Address:
Nottingham, Nottingham, United Kingdom
Country:
United Kingdom
Status:
Active
Similar Organizations
FibromEd
FibromEd is provides a research and experimental development on biotechnology.
GeneWake GmbH
GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology.
Islexa
Islexa is provides research and experimental development on biotechnology.
TFL Bearing
TFL focuses on the research and development of bearing technology.
Current Employees Featured
Founder
More informations about "448 THERAPEUTICS"
448 Therapeutics - Products, Competitors, Financials, Employees ...
448 Therapeutics works in research and experimental development on biotechnology. Use the CB Insights Platform to explore 448 Therapeutics's full profile. 448 Therapeutics - Products, โฆSee details»
448 THERAPEUTICS - Tech Stack, Apps, Patents & Trademarks
448 THERAPEUTICS focuses on the research and experimental development of biotechnology.See details»
448 Therapeutics Ltd Company Number 10311878 Prepared By โฆ
Apr 22, 2024 Name 448 THERAPEUTICS LTD. Company Number 10311878. Company Type Private Limited Company. Company Status Active. SIC Code 72110 Research and โฆSee details»
448 THERAPEUTICS LTD - Companies House
Oct 29, 2024 More for 448 THERAPEUTICS LTD (10311878) Registered office address Biocity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire, England, NG1 1GF . Company โฆSee details»
Mark Graham - Founder @ 448 THERAPEUTICS - Crunchbase
Mark Graham is the Founder at 448 THERAPEUTICS. Jobs. Edit Jobs Section. Number of Current Jobs 2. Number of Past Jobs 1. Mark Graham has 2 current jobs as Founder at 448 โฆSee details»
iTeos Provides Business Updates and Clinical Development
Jan 9, 2023 iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. โฆSee details»
GSK and iTeos Therapeutics announce development and โฆ
Obligation to share responsibility and costs for the global development of EOS-448; our plan to accelerate and expand the clinical development of EOS-448 and other in-house pipeline โฆSee details»
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
Jun 15, 2021 GlaxoSmithKline GSK announced an agreement to acquire joint development and commercialization rights to iTeos Therapeuticsโ ITOS early-stage cancer candidate, EOS-448, โฆSee details»
448 Therapeutics - CB Insights
Explore {448 Therapeutics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. 448 Therapeutics CEO, โฆSee details»
GSK joins anti-TIGIT push with $625m upfront iTeos deal
Dec 16, 2024 The deal includes $625 million in upfront fees to secure rights to EOS-448, which is currently in a phase 1 dose-ranging trial in advanced solid tumours in combination with โฆSee details»
GSK, iTeos take stock after Roche's TIGIT setback
2 days ago iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for โฆSee details»
GSK pays iTeos $625M upfront to join Merck, Roche and the rest โฆ
Jun 14, 2021 GlaxoSmithKline is paying iTeos Therapeutics $625 million upfront for rights to phase 1 anti-TIGIT monoclonal antibody EOS-448. The deal sets GSK up to challenge Bristol โฆSee details»
GSK, iTeos Therapeutics to co-develop and co-commercialise โฆ
GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody presently under phase I โฆSee details»
GSK and iTeos partner to develop antibody for cancer treatment
Jun 14, 2021 GlaxoSmithKline and iTeos Therapeutics have signed an agreement to jointly develop and market a monoclonal antibody, EOS-448, as a potential cancer treatment. A โฆSee details»
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung โฆ
Jul 9, 2024 iTeos will secure $35m from GlaxoSmithKline because it has reached its development-based milestone of treating the first patient in the Phase III trial of its TIGIT โฆSee details»
iTeos Therapeutics | iTeos Presents New Data for Anti-TIGIT โฆ
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody ...See details»
Preliminary data from Phase I first-in-human study of EOS884448, โฆ
โข EOS-448 is a fully human a-TIGIT Ab with multiple MoA โข EOS-448 demonstrated good safety profile and strong anti-tumor activity in preclinical development Objective of the Ph1 Study โข To โฆSee details»
Anti-TIGITmAb FcyR-Engaging - iTeos
EOS-448 is an anti-TIGIT human immunoglobulin G1, or IgG1, antibody that we are developing to inhibit the immunosuppressive activity of TIGIT. We have designed EOS-448 to engage with โฆSee details»
$2.4 million bond set for members of '448 Whole Lotta Weight'
6 days ago GREENVILLE, S.C. โ Two members of the '448 Whole Lotta Weight' organization had bond set at more than $2 million for their involvement in a dangerous drug trafficking โฆSee details»